Selinexor- Karyopharm Therapeutics
Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; NEXPOVIO; ONO 7705; Selinisso; TP-53; XPOVIOLatest Information Update: 04 Sep 2024
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Cardiff University; Grupo Espanol de Investigacion en Sarcomas; Karyopharm Therapeutics; Menarini; Ono Pharmaceutical; Promedico; University of Texas Southwestern Medical Center
- Class Acrylamides; Anti-infectives; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Foot disorder therapies; Hydrazines; Pyrazines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma; Multiple myeloma
- Phase III Endometrial cancer; Liposarcoma; Myelofibrosis
- Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Colorectal cancer; COVID 2019 infections; Malignant melanoma; Ovarian cancer; Peripheral T-cell lymphoma; Thrombocytopenia; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
- Phase I/II Gastrointestinal stromal tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Phase I Liver cancer
- No development reported B-cell lymphoma; Cervical cancer; Chronic lymphocytic leukaemia; Extranodal NK-T-cell lymphoma; Glioma; HER2 positive breast cancer; Neuroendocrine tumours; Osteosarcoma; Sepsis; Soft tissue sarcoma
- Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Glioblastoma; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer
Most Recent Events
- 23 Aug 2024 Karyopharm Therapeutics terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic, Combination Therapy, Second line therapy or greater, First-line therapy, Recurrent) due to lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab (NCT04768881)
- 06 Aug 2024 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Malaysia (PO)
- 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Non-small Cell Lung Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)